Sanofi Returning Zantac OTC Heartburn Remedy Brand To US Market Formulated With Famotidine
Consumer Health Gets Little Mention In Q1 Results After Sales Dip 7%
Executive Summary
Along with its Q1 results including a 7.3% drop in consumer health sales to €1.11bn ($1.35bn), Sanofi announces 10-mg famotidine tablets branded Zantac 360° will be available in the US in June.
You may also be interested in...
First Recalls, Now Investors' Concerns Over Ranitidine Litigation Take Pharmas For Wild Ride
Host of complaints in US courts, seeking damages or alleging ranitidine caused various cancers, followed FDA’s 2020 findings of NDMA levels exceeding allowable limits in some samples provoked Litigation is starting to come to trial, the first set for 22 August in Illinois and a bellwether case due to begin in California in February 2023.
US OTC Switch For Cialis At Top Of To-Do List For Sanofi’s North American Consumer Health Chief
Andrew Loucks moves to Sanofi from helm of consumer health and technology firm Sensory Cloud as business navigates gaining US OTC heartburn market share for Zantac brand, which it relaunched with famotidine replacing ranitidine as the active ingredient.
Sanofi Appealing Findings In Review Of Zantac 360 Doctor-Recommended Claims Challenged By J&J
French pharma disagrees with NAD finding, following review of a claims made in online and social media ads, retailers' websites and a TV commercial, that the claim “#1 doctor recommended medicine” for Zantac 360 refers to the brand and not famotidine, also used in other OTC heartburn remedies, including Pepcid.